Adocia and Lilly terminate collaboration

barbara.lempert

reacquires exclusive development rights to ultra-fast acting insulin analog

Lyon, France, July 29, 2013 – Adocia (NYSE Euronext Paris: FR0011184241 – ADOC), a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announced today that it had agreed with Eli and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia’s BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the .

“We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone(R) technology” said Gerard Soula, President and CEO, Adocia.

“Our plan is to test a BioChaperone(R) insulin analog formulation on type I diabetic patients. For this, we intend to conduct a clinical trial, before year end in Germany, on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet(R), our formulation of human insulin” said Olivier Soula, deputy general manager and director R&D, Adocia.
 
The company has a strong financial position enabling the development of this priority project at its own expense.
 
Next scheduled events
September 5, 2013: Publication of mid-year financial statements as of June 30, 2013.
September 6, 2013: Presentation meeting to investors (SFAF).

About Adocia :
“Innovative medicine for everyone, everywhere”
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.
Adocia is specialized in insulin therapy and the treatment of…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS